Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ivision Tech S.P.A. ( (IT:IVN) ) just unveiled an update.
iVision Tech has announced that its iSee technological glasses have been registered as a Class 1 Medical Device with the Ministry of Health. This registration, along with the CE declaration of conformity, certifies that the glasses meet EU safety and performance requirements. The iSee glasses, designed for blind users, enhance autonomy and safety by recording the surrounding space and objects. The product is available for order and distribution, marking a significant step in improving the lives of visually impaired individuals and strengthening iVision Tech’s position in the medical device market.
The most recent analyst rating on (IT:IVN) stock is a Buy with a EUR3.30 price target. To see the full list of analyst forecasts on Ivision Tech S.P.A. stock, see the IT:IVN Stock Forecast page.
More about Ivision Tech S.P.A.
iVision Tech S.p.A. is an innovative SME specializing in the design and production of acetate eyeglass frames and sunglasses, as well as combined glasses. The company, known for its ‘Made in Italy’ manufacturing, operates a 5,000 square meter plant in Friuli-Venezia Giulia and collaborates with international luxury fashion brands. It manages a comprehensive production cycle and has a division dedicated to research and development for technological innovations in eyewear. iVision Tech also owns the historic French eyewear brand Henry Jullien and has expanded into the retail market and ophthalmic lens production.
Average Trading Volume: 29,552
Technical Sentiment Signal: Buy
Current Market Cap: €16.92M
For detailed information about IVN stock, go to TipRanks’ Stock Analysis page.